Case-Based Learning on Choroidal Perfusion Abnormalities in Progressive Vision Disorders

Abstract

Choroidal perfusion abnormalities play a pivotal role in the pathogenesis and progression of various vision-threatening disorders. This review utilizes a case-based learning approach to elucidate the mechanisms, clinical presentations, diagnostic strategies, and management of choroidal perfusion disturbances, integrating recent evidence and guideline-based recommendations. By synthesizing findings from contemporary studies and clinical guidelines, this article aims to enhance clinicians\' understanding of choroidal vascular disorders and improve patient outcomes through early recognition and targeted interventions.

Introduction

Vision disorders related to choroidal perfusion abnormalities present significant diagnostic and therapeutic challenges in ophthalmology. The choroid, a highly vascularized structure, supplies oxygen and nutrients to the outer retina. Abnormal perfusion can result in irreversible damage and progressive vision loss if not promptly identified and managed. Case-based learning provides a practical framework for understanding the complex interplay between systemic and ocular factors that contribute to choroidal dysfunction, enhancing clinical acumen in real-world settings.

Epidemiology / Disease Burden

Choroidal perfusion abnormalities are implicated in a spectrum of disorders such as age-related macular degeneration (AMD), central serous chorioretinopathy (CSCR), and polypoidal choroidal vasculopathy (PCV). The global burden of these diseases is substantial, with AMD alone affecting over 190 million individuals worldwide. Epidemiological studies suggest that choroidal vascular impairment is a common final pathway in both prevalent and rare progressive vision disorders, contributing notably to morbidity in aging populations. The increasing prevalence of metabolic syndrome and cardiovascular comorbidities has further amplified the disease burden linked to choroidal vascular compromise.

Pathophysiology

The pathophysiology of choroidal perfusion abnormalities centers on disruption of the choriocapillaris and larger choroidal vessels, leading to ischemia, hypoxia, and subsequent retinal pigment epithelium (RPE) dysfunction. Mechanistically, factors such as endothelial dysfunction, vascular remodeling, and immune-mediated injury are involved. In AMD, for instance, chronic hypoperfusion may trigger neovascularization, while in CSCR, corticosteroid-induced vascular hyperpermeability is implicated. Advanced imaging modalities, including optical coherence tomography angiography (OCTA), have elucidated microvascular changes, enhancing our understanding of disease mechanisms and progression.

Risk Factors

Multiple systemic and local risk factors contribute to choroidal perfusion abnormalities. Age is a predominant risk factor, with cumulative vascular wear and tear leading to compromised choroidal blood flow. Hypertension, diabetes mellitus, dyslipidemia, and smoking increase the risk by promoting atherosclerosis and microvascular disease. Ocular risk factors include high myopia, prior ocular surgery, and chronic inflammation. Genetic predispositions, notably polymorphisms in complement factor H (CFH) and ARMS2, have been linked to AMD and related choroidal disorders. Exogenous corticosteroid use and psychological stress are recognized triggers in CSCR.

Clinical Features

Clinical presentations vary depending on the underlying disorder and the extent of perfusion impairment. Common symptoms include progressive central or paracentral vision loss, metamorphopsia, and scotomas. Fundoscopic examination may reveal choroidal thinning, serous retinal detachments, or subretinal hemorrhages. In neovascular AMD, choroidal neovascular membranes and exudation are hallmark findings. Multimodal imaging, including fluorescein and indocyanine green angiography, can demonstrate delayed or patchy choroidal filling and leakage patterns specific to the underlying pathology.

Diagnosis

Timely and accurate diagnosis hinges on a combination of clinical assessment and advanced imaging modalities. OCTA has emerged as a critical tool for non-invasive visualization of the choriocapillaris and deeper choroidal vasculature. Indocyanine green angiography remains valuable for identifying choroidal neovascularization and polypoidal lesions. Systemic evaluation for cardiovascular risk factors is essential, particularly in older adults. Differential diagnoses should encompass retinal vascular occlusions, optic neuropathies, and inflammatory chorioretinopathies to ensure comprehensive evaluation and tailored management.

Treatment & Management

Management strategies are guided by the underlying etiology and disease stage. Anti-vascular endothelial growth factor (VEGF) agents are the mainstay for neovascular AMD and PCV, effectively reducing exudation and stabilizing vision. In CSCR, risk factor modification—particularly cessation of corticosteroids—and observation are often sufficient, with photodynamic therapy reserved for chronic or recurrent cases. Systemic risk factor optimization, including blood pressure and glycemic control, is integral to reducing recurrence and progression. Multidisciplinary collaboration is frequently required for complex cases with systemic involvement.

Recent Advances / Emerging Therapies

Recent advances in choroidal imaging and molecular therapy have transformed the management of choroidal perfusion abnormalities. The advent of swept-source OCT and wide-field OCTA has enabled in-depth visualization of choroidal structure and perfusion in vivo. Novel therapeutics, such as complement inhibitors (e.g., pegcetacoplan) and gene therapy approaches, are under investigation for AMD and related disorders. Early clinical trials of oral mineralocorticoid receptor antagonists have shown promise in CSCR by modulating choroidal vascular permeability. Personalized medicine, leveraging genetic and biomarker profiling, is poised to further refine risk stratification and therapeutic targeting.

Guideline Recommendations

Current clinical guidelines from organizations such as the American Academy of Ophthalmology (AAO) and European Society of Retina Specialists (EURETINA) emphasize early detection, risk factor modification, and individualized therapy. For AMD, regular screening and prompt initiation of anti-VEGF therapy are recommended upon evidence of neovascularization. In CSCR, guidelines advocate conservative management for acute cases and intervention for chronic, vision-threatening disease. Routine assessment of systemic comorbidities and patient education are strongly advised to improve outcomes and prevent recurrence.

Conclusion

Choroidal perfusion abnormalities represent a critical, yet often underappreciated, mechanism underlying progressive vision disorders. Through integration of case-based learning, recent evidence, and guideline-based recommendations, clinicians can enhance diagnostic accuracy and optimize management strategies. Advances in imaging and therapeutics offer new hope for patients, but ongoing research and multidisciplinary collaboration remain essential to address the complexities of choroidal vascular disease and mitigate its impact on vision health.